Analyst Price Targets — QTTB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 10, 2026 4:20 pm | Joseph Pantginis | H.C. Wainwright | $13.00 | $5.99 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Q32 Bio Inc. (QTTB): "2026 should be highlighted by key clinical data" |
| December 5, 2024 9:10 pm | Etzer Darout | BMO Capital | $64.00 | $23.69 | StreetInsider | BMO Capital Starts Q32 Bio Inc. (QTTB) at Outperform |
| October 16, 2024 6:22 am | Jay Olson | Oppenheimer | $80.00 | $48.47 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Q32 Bio Inc. (QTTB) |
| September 11, 2024 5:27 am | Derek Archila | Wells Fargo | $95.00 | $50.61 | StreetInsider | Wells Fargo Starts Q32 Bio Inc. (QTTB) at Overweight |
| May 21, 2024 6:22 am | Thomas Smith | Leerink Partners | $54.00 | $30.20 | TheFly | Q32 Bio initiated with an Outperform at Leerink |
| April 10, 2024 4:02 pm | Jay Olson | Oppenheimer | $50.00 | $21.48 | StreetInsider | Oppenheimer Starts Q32 Bio Inc. (QTTB) at Outperform |
| April 2, 2024 5:02 am | Christopher Raymond | Raymond James | $45.00 | $18.00 | TheFly | Q32 Bio initiated with an Overweight at Piper Sandler |
| April 2, 2024 3:46 am | Allison Bratzel | Piper Sandler | $45.00 | $18.00 | StreetInsider | Piper Sandler Starts Q32 Bio Inc. (QTTB) at Overweight, 'we would be buyers here' |
Latest News for QTTB
WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m.
The consensus price target hints at a 97.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Q32 Bio is now largely a single-asset story centered on Bempikibart in alopecia areata, with mid-2026 topline data as the key catalyst. Management sold ADX-097 to Akebia, which brings milestone and royalty payments as an extra while concentrating its efforts on Bempikibart's R&D. Bempikibart's prior data and ongoing OLE data suggest durable responses and possible remission. This keeps my long-term alopecia areata…
MGY, ESCA, and QTTB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 27, 2026.
DNN, CM, MGY, QTTB and FLXS have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QTTB.
U.S. House Trading
No House trades found for QTTB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.